Revivent TC™ TransCatheter Ventricular Enhancement System

A Hybrid Transcatheter-Thoracoscopic Approach to Less Invasive Ventricular Enhancement.

The Revivent TC System* extends the Less Invasive Ventricular Enhancement™ (LIVE™) procedure, pioneered by BioVentrix as an alternative to conventional surgical ventricular restoration (SVR), by enabling a closed-chest approach. Placement of the Revivent TC System is done without sternotomy or ventriculotomy, so the need for cardiopulmonary bypass is eliminated. The proprietary transcatheter delivery system enables volume reduction of the left ventricle (LV) via placement of anchors designed to exclude scarred myocardial tissue from the left ventricle while also restoring its more natural conical shape. Recent peer-reviewed studies have found that LV volume is the best predictor of survival in ischemic cardiomyopathy patients.1

The Revivent™ Myocardial Anchoring System and Revivent TC System use identical titanium micro-anchoring devices for treating the underlying cause of heart failure. The Revivent TC System employs a hybrid endovascular technique performed in the hybrid cath lab that will allow physicians to treat a more fragile patient population by eliminating the risks of open surgical intervention.

Clinical Benefit Comparison for the Revivent and the Revivent TC Systems

Clinical Benefits Revivent Revivent TC Under Clinical Study
Directly reduces LV radius Yes Yes
Reduces LV wall tension Yes Yes
Returns the LV to a more conical shape Yes Yes
Treats the progression of LV enlargement Yes Expected
Treats the cause of heart failure symptoms Yes Expected
One-year durability data Mean LVESVI
57.3 ml/m2
Clinical results forthcoming
Improvements in NYHA class, QOL score & six-minute walk test Yes Expected
Device Placement Revivent Revivent TC Under Clinical Study
Procedure descrption Trans-epicardial surgical & less invasive Hybrid transcatheter-thoracoscopic
Physician team Cardiac surgeon Cardiac surgeon & cardiologist
Procedure location Operating room suite Interventional hybrid lab
Requires cardiopulmonary bypass support Optional No
Device placed concurrently with other procedures or as a stand-along procedure Either Either
Requires ventriculotomy No No
Less invasive approach than conventional SVR Yes Yes

The Revivent TC™ TransCatheter Ventricular Enhancement System requires regulatory approval and is not yet commercially available.

1Kramer DG et al. Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction: A Meta-Analytic Approach. J Am Coll Cardiol. 2010; 56(5):392-406.